CCT-018159

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H20N2O4
Molecular Weight	352.3838
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=C(O)C=C(O)C(=C1)C2=NNC(C)=C2C3=CC=C4OCCOC4=C3

InChI

InChIKey=OWPMENVYXDJDOW-UHFFFAOYSA-N

InChI=1S/C20H20N2O4/c1-3-12-8-14(16(24)10-15(12)23)20-19(11(2)21-22-20)13-4-5-17-18(9-13)26-7-6-25-17/h4-5,8-10,23-24H,3,6-7H2,1-2H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula	C20H20N2O4
Molecular Weight	352.3838
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17431102 | https://www.ncbi.nlm.nih.gov/pubmed/17332351 | https://www.ncbi.nlm.nih.gov/pubmed/16818523

CCT-018159 is a novel inhibitor of heat shock protein (Hsp) 90 with potential anticancer activity. CCT-018159 inhibited human HSP90beta with comparable potency to 17-AAG and with similar ATP-competitive kinetics. The mean cellular GI(50) value of CCT-018159 across a panel of human cancer cell lines, including melanoma, was 5.3 mumol/L. CCT-018159 caused cell cytostasis associated with a G(1) arrest and induced apoptosis. CCT-018159 also inhibited key endothelial and tumor cell functions implicated in invasion and angiogenesis. CCT-018159 has the potential to inhibit invasion and angiogenesis as part of combinatorial anticancer effects. CCT-018159 is still in the preclinical development stage for the treatment of cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Heat shock protein HSP 90-beta 13 Target ID: CHEMBL4303 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17332351 \| https://www.ncbi.nlm.nih.gov/pubmed/15955698	Inhibitor 8297		3.2 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: http://adisinsight.springer.com/drugs/800018517 https://www.ncbi.nlm.nih.gov/pubmed/25579569	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target.	2015	25579569
Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells.	2015 Aug	25280813
Potential role of Hsp90 in rat islet function under the condition of high glucose.	2016 Aug	26997509

Patents

Sample Use Guides

In Vivo Use Guide

Mice: CCT-018159 was administered i.v. and p.o., at 20 mg/kg or in combination with other heat shock protein 90 inhibitors at 4 mg/kg each.

Route of Administration: Other

In Vitro Use Guide

The IC50 value for CCT-018159 against the ATPase activity of full-length yeast Hsp90 at 400 umol/L ATP was 6.6 +/- 0.5 umol/L. At 10 and 100 umol/L CCT-018159, no inhibition was observed against human HSP72. ATPase or the decatenation activity of human topoisomerase II. In a panel of 20 representative kinases, CCT-018159 at 50 umol/L showed <50% inhibition in 13 of these kinases. The mean cellular GI(50) value of CCT-018159 across a panel of human cancer cell lines, including melanoma, was 5.3 umol/L.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:30:47 GMT 2023` Edited by `admin` on `Sat Dec 16 10:30:47 GMT 2023`
Record UNII	55H1ZOI1NL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CCT-018159

Common Name

English

1,3-BENZENEDIOL, 4-(4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-5-METHYL-1H-PYRAZOL-3-YL)-6-ETHYL-

Systematic Name

English

Code System Code Type Description

FDA UNII

55H1ZOI1NL